RxDoctor Payments Data

Tierra Richardson

Gerontology · Bowie, MDNPI 1740796945

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$709in general payments, 2019–2025

Across 40 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$152
  • AstraZeneca$109
  • Lilly USA, LLC$92
  • Merck$70
  • Jazz Pharmaceuticals Inc.$61
  • Currax Pharmaceuticals LLC$60
  • plus $166 from 6 others

What the payments were for

  • Food & beverage$709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$709 in reported general payments places this provider in the 70th percentile of 108 gerontology providers in Maryland.

See all gerontology providers in Maryland

Medicare billing

Part B allowed, 2024
$62,951
Medicare patients
231
Services billed
704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate25$15,167
EliquisApixaban15$13,581
Albuterol Sulfate HfaAlbuterol Sulfate65$1,729
Atorvastatin Calcium161$1,687
Levothyroxine Sodium33$1,616
Amlodipine Besylate154$1,378
Ventolin HfaAlbuterol Sulfate12$697
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$691
Rosuvastatin Calcium37$615
Diclofenac Sodium21$526
Pantoprazole Sodium27$423
Ezetimibe11$419
Potassium Chloride18$398
Olmesartan Medoxomil13$392
Metoprolol Succinate32$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$70$15,16725 claims
PfizerEliquis$17$13,58115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 108 gerontology providers in Maryland.

Other gerontology in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →